End-stage kidney disease

Definition

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. The kidneys remove waste and excess water from the body.

Alternative Names

Renal failure - end stage; Kidney failure - end stage; ESRD

Causes

End-stage kidney disease (ESRD) is when the kidneys are no longer able to work at a level needed for day-to-day life.

The most common causes of ESRD in the U.S. are diabetes and high blood pressure. These conditions can affect your kidneys.

ESRD almost always comes after chronic kidney disease. The kidneys may slowly stop working over 10 - 20 years before end-stage disease results.

Symptoms

Symptoms may include:

Other symptoms may include:

Exams and Tests

Your health care provider will perform a physical exam and order blood tests. Most people with this condition have high blood pressure.

Patients with end-stage kidney disease will make much less urine, or urine production may stop.

End-stage kidney disease changes the results of many tests. Patients receiving dialysis will need these and other tests done often:

This disease may also change the results of the following tests:

Treatment

Dialysis or kidney transplantation is the only treatment for this condition.

For more information on these treatments, see:

Your doctor may also put you on medicine to control your blood pressure.

You may need to make changes in your diet.

For more information, see: Diet and chronic kidney disease

Other treatment depends on your symptoms but may include:

You should be up-to-date on important vaccinations, including:

Support Groups

See: Kidney disease support group

Outlook (Prognosis)

End-stage kidney disease leads to death if you do not have dialysis or a kidney transplant. However, both of these treatments can have risks. The outcome is different for each person.

Possible Complications

Prevention

Treatment of chronic kidney disease may delay or prevent progression to ESRD. Some cases may not be preventable.

References

Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med. 2010 Nov 4;363(19):1833-45. Review. PubMed PMID: 21047227.

Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010 Apr 8;362(14):1312-24.

Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. NEngl J Med. 2010 Jan 7;362(1):56-65.

KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.

KDOQI: National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(5 Suppl 3):S16-S85.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23-33.


Review Date: 9/21/2011
Reviewed By: David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc., andHerbert Y. Lin, MD, PHD, Nephrologist, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com